Meet the Little-Known Chinese CAR-T Biotech Up More Than 500% Since June 2017
The company reported positive results from early studies in 35 patients with a type of blood cancer last year. Source: BioSpace
The company reported positive results from early studies in 35 patients with a type of blood cancer last year. Source: BioSpace
The company is addressing the FDA’s complaints regarding manufacturing practices, which stem from a routine inspection in January, Source: BioSpace
ImmunoGen gave a pipeline progress report and 2017 operating results last week. Source: BioSpace
Astellas will gain Universal Cells' proprietary Universal Donor Cell technology to create cell therapy products that do not require HLA matching. Source: BioSpace
The company plans to submit for regulatory approvals pending additional data from the ongoing Taltz development program later this year. Source: BioSpace
Teva and Mylan are looking over their shoulders this morning after the FDA gave Novartis and Momenta the green light for their Copaxone copycat drug. Source: BioSpace
The company plans to add approximately 100 positions at the Center by 2020. Source: BioSpace
The FDA approved Vertex's Symdeko for cystic fibrosis in patients ages 12 and older with two copies of the F508del mutation. Source: BioSpace
The acquisition will strengthen Charles River's position as a global early-stage CRO, expanding its client base and service portfolio. Source: BioSpace
Bob Hugin announced his campaign on Monday in an email. Source: BioSpace